Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment.

28 May 2014

Researchers identify mutated gene common to rare form of pancreatic cancer

Researchers at the University of California, San Diego School of Medicine have identified a mutated gene common to adenosquamous carcinoma (ASC) tumors - the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer.

26 May 2014

Space Station science: Microgravity on human thyroid carcinoma cells

The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits.

21 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.

19 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

A study which will be published in the May 2014 issue of Experimental Biology and Medicine was aimed at determining whether an EGFR-targeted therapy combined with chemo-radiotherapy can improve local tumor control effectively, compared to cytotoxic agents or irradiation alone.

14 May 2014

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

A new paper by a team of researchers led by Zachary T. Schafer, Coleman Assistant Professor of Cancer Biology in the Department of Biological Sciences at the University of Notre Dame, offers important new insights into the role carcinoma-associated fibroblasts (CAFs) play in tumor biology.

9 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Carcinoma News and Research

Further Reading

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ArQule to present tivantinib clinical trial data at ASCO 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

Researchers identify mutated gene common to rare form of pancreatic cancer

Space Station science: Microgravity on human thyroid carcinoma cells

Vandetanib delays disease progression in elderly NSCLC patients

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Study to investigate use of OCT in collaboration with Melanoma Institute of Australia

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

EntreMed reports net loss of $1.5M in first quarter 2014

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

New paper offers new insights into role carcinoma-associated fibroblasts play in tumor biology

Hepatocellular carcinoma on the rise among Mexican Americans

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News